PO.TB10.07 · 肿瘤生物学

空间转录组学揭示胸腺上皮肿瘤新辅助治疗后与临床反应相关的独特肿瘤微环境

Spatial transcriptomics reveal distinct tumor microenvironment associated with clinical response in thymic epithelial tumors after neoadjuvant therapy

编号 6197 展板 11 时间 4/21 02:00–05:00 区域 Section 31 主讲 Hyunsu Kim, PhD
分会场 Spatial Niches and Functional Boundaries within the Tumor Microenvironment 2
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Hyunsu Kim1, Jinyong Kim1, Hyun-Ae Jung1, Jong-Mu Sun1, Se-Hoon Lee1, Jin Seok Ahn1, Myung-Ju Ahn1, Yeong Jeong Jeon2, Junghee Lee2, Jong Ho Cho2, Hong Kwan Kim2, Yong Soo Choi2, Seong Yong Park2, Woong-Yang Park3, Yoon-La Choi4, Sehhoon Park1

1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of,2Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of,3Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea, Republic of,4Department of Pathology & Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of

摘要 Abstract

中文摘要
背景:胸腺上皮肿瘤(TETs)是罕见的恶性肿瘤,大多以手术切除作为标准治疗方法。然而,复发率仍然很高,且免疫治疗可导致免疫相关不良事件,这凸显了改进治疗方法和预测性生物标志物的必要性。在本研究中,TET患者在手术前接受了三个周期的新辅助免疫化疗。我们旨在表征肿瘤微环境(TME),以确定其与治疗反应的关联。 方法:我们对19例接受新辅助免疫化疗患者的手术标本进行了18例单细胞RNA测序和15例空间转录组学分析。主要病理缓解(MPR)定义为切除标本中存活肿瘤细胞少于10%。患者被分为三个病理反应组——胸腺癌(TC)伴MPR、TC非MPR,或胸腺瘤(TM)非MPR。 结果:细胞组成和配体-受体相互作用网络分析揭示了根据病理反应组划分的不同TME差异。在TC中,伴MPR的肿瘤以广泛的免疫浸润、三级淋巴结构(TLS)形成以及显著的恶性细胞坏死为特征。这种免疫学上的"热"TME表现为淋巴细胞与树突状细胞(DCs)之间的强烈相互作用。相反,TC非MPR的TME以胸腺上皮细胞(TECs)为主。在肿瘤核心内,这些TECs通过促进浸润性CD8+ T细胞的耗竭并驱动肿瘤相关巨噬细胞向M2样状态极化,协调形成局部免疫抑制。这种抑制性niche进一步因DC稀缺而加剧。在TM中,非MPR肿瘤以散在的皮质TECs(cTECs)和胸腺细胞为特征,伴有效应T细胞的稀疏浸润。值得注意的是,cTECs通过促进胸腺细胞的存活和滞留、同时损害CD8+ T细胞的肿瘤杀伤功能,维持了一种不成熟的TME。将进一步阐明这些TME动态的详细细胞间相互作用结果将在会上展示。 结论:我们的研究发现,TETs对新辅助治疗的反应与TME的独特空间特征密切相关。本研究利用整合的单细胞和空间多组学数据,为TME提供了宝贵见解,并可能为改善TETs临床结局的治疗策略提供理论依据。
查看英文原文 English abstract
Background : Thymic epithelial tumors (TETs) are rare malignancies, mostly treated with surgical resection as the standard approach. However, recurrence rates remain high and immunotherapy can lead to immune-related adverse events, highlighting the need for improved therapies and predictive biomarkers. In this study, TET patients were administered three cycles of neoadjuvant immunochemotherapy prior to surgery. We aimed to characterize the tumor microenvironment (TME) to identify the association with treatment response. Methods : We performed 18 single-cell RNA sequencing and 15 spatial transcriptomics on surgical specimens from 19 patients treated with neoadjuvant immunochemotherapy. Major pathological response (MPR) was defined as less than 10% viable tumor cells in resected specimens. Patients were stratified into three pathological response groups ⎯ thymic carcinoma (TC) with MPR, TC non-MPR, or thymoma (TM) non-MPR. Results : Analysis of cell composition and ligand-receptor interaction networks revealed distinct TME differences according to pathological response group. In TC, tumors with MPR were characterized by extensive immune infiltration, tertiary lymphoid structures (TLS) formation, and prominent malignant cell necrosis. This immunologically hot TME featured robust interactions between lymphocytes and dendritic cells (DCs). Conversely, the TC non-MPR TME was dominated by thymic epithelial cells (TECs). Within the tumor core, these TECs orchestrated a localized immunosuppression by promoting the exhaustion of infiltrating CD8+ T cells and driving the polarization of tumor-associated macrophages into an M2-like state. This suppressive niche was further compounded by a scarcity of DC. In the context of TM, the non-MPR tumors was defined by scattered cortical TECs (cTECs) and thymocytes, alongside a sparse infiltration of effector T cells. Notably, cTECs maintained an immature TME by promoting thymocyte survival and retention while concurrently impairing the tumor-killing functionality of CD8+ T cells. Detailed cell-to-cell interaction results that further elucidate these TME dynamics will be presented. Conclusions : Our findings that responses to neoadjuvant therapy in TETs are closely associated with distinct spatial characterization of the TME. Leveraging integrated single-cell and spatial multi-omics data, this study provides valuable insights into the TME and may inform a rationale for therapeutic strategies to improve clinical outcomes in TETs.
利益披露 Disclosure
H. Kim, None.. J. Kim, None.. H. Jung, None.. J. Sun, None.. S. Lee, None.. J. Ahn, None.. M. Ahn, None.. Y. Jeon, None.. J. Lee, None.. J. Cho, None.. H. Kim, None.. Y. Choi, None.. S. Park, None.. W. Park, None.. Y. Choi, None.. S. Park, None.

← 返回 AACR 2026 检索